NYSE:EQR News 9 January 2026

Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Equity Residential shares fell 3.8% to $60.46 after BMO Capital downgraded the stock, citing softening rental markets in major coastal cities. The drop followed news of a $400 million sale of three properties to JRK Property Holdings. Other large apartment REITs also traded lower. Investors are watching for upcoming U.S. inflation data and Equity Residential’s earnings on Feb. 2.

9 January 2026

NYSE:AVB·NYSE:EQR·Real Estate·Stock Market

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

7 February 2026

IBM shares closed up 3.1% at $298.93 Friday, outperforming some tech peers as U.S. stocks rebounded. The move followed IBM’s announcement of a Missile Defense Agency contract and comes ahead of a Feb. 12 Confluent shareholder vote on IBM’s $11 billion acquisition proposal.

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026

Philip Morris International closed at $182.81, up 0.45%, after raising its 2026 profit outlook on stronger nicotine pouch sales. Fourth-quarter adjusted EPS rose to $1.70, with net revenue up 6.8% to $10.36 billion. CEO Jacek Olczak said updated Zyn products are pending regulatory approval. The next dividend declaration is set for March 5, 2026.

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

7 February 2026

Novartis shares closed up 0.6% in Zurich at 119.96 francs Friday, with U.S. ADRs gaining 1.5%. The company broke ground on a new San Diego research center and reported a positive draft reimbursement recommendation for Kisqali in Canada. Investors are watching for the March 6 annual meeting and March 10 ex-dividend date tied to a proposed 3.70-franc payout.

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026

AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.

NYSE:EQR News 9 January 2026

Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Stock Market Today

IBM stock price jumps 3% into weekend as Confluent vote and dividend date near

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

AstraZeneca stock price: What could move AZN next week as earnings loom